Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-372]
 AGENCY: Drug Enforcement Administration, Department of Justice.
 ACTION: Order with opportunity for comment.
 SUMMARY: The applications for exempt chemical preparations received by the Drug Enforcement Administration between April 1, 2021, and June 30, 2021, as listed below, were accepted for filing and have been approved or denied as indicated.
 DATES: Interested persons may file written comments on this order in accordance with 21 CFR 1308.23(e). Electronic comments must be submitted, and written comments must be postmarked, on or before March 22, 2022. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
 ADDRESSES: To ensure proper handling of comments, please reference “Docket No. DEA-372” on all correspondence, including any attachments. *Electronic comments:*
                         Drug Enforcement Administration encourages that all comments be submitted through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or to attach a file for lengthier comments. Please go to 
                        *http://www.regulations.gov*
                         and follow the online instructions at that site for submitting comments. Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on 
                        *Regulations.gov.*
                         If you have received a comment tracking number, your comment has been successfully submitted and there is no need to resubmit the same comment. *Paper comments:*
                         Paper comments that duplicate the electronic submission are not necessary and are discouraged. Should you wish to mail a comment 
                        *in lieu of*
                         an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.
 FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Ph.D., Diversion Control Division, Drug Enforcement Administration; Telephone: (571) 362-8201.


SUPPLEMENTARY INFORMATION: Posting of Public Comments Please note that all comments received are considered part of the public record and made available for public inspection online at 
                    *http://www.regulations.gov*
                     and in the DEA's public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter. The Freedom of Information Act applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase “PERSONAL IDENTIFYING INFORMATION” in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted. If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase “CONFIDENTIAL BUSINESS INFORMATION” in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. Comments containing personal identifying information and confidential business information identified as directed above will generally be made publicly available in redacted form. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to 
                    *http://www.regulations.gov*
                     may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as confidential. An electronic copy of this document is available at 
                    *http://www.regulations.gov*
                     for easy reference. Legal Authority Section 201 of the Controlled Substances Act (CSA) (21 U.S.C. 811) authorizes the Attorney General, by regulation, to exempt from certain provisions of the CSA certain compounds, mixtures, or preparations containing a controlled substance, if he finds that such compounds, mixtures, or preparations meet the requirements detailed in 21 U.S.C. 811(g)(3)(B).[1]
                    
                     The Drug Enforcement Administration (DEA) regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria by which the DEA Assistant Administrator may exempt a chemical preparation or mixture from certain provisions of the CSA. The Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which exemptions are granted and modify the scope of exemptions at any time. Exempt Chemical Preparation Applications Submitted Between April 1, 2021, and June 30, 2021 The Assistant Administrator received applications between April 1, 2021, and June 30, 2021, requesting exempt chemical preparation status detailed in 21 CFR 1308.23. Pursuant to the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart I below is intended for laboratory, industrial, educational, or special research purposes and not for general administration to a human being or animal and either: (1) Contains no narcotic controlled substance and is packaged in such a form or concentration that the packaged quantity does not present any significant potential for abuse; or (2) contains either a narcotic or non-narcotic controlled substance and one or more adulterating or denaturing agents in such a manner, combination, quantity, proportion, or concentration that the preparation or mixture does not present any potential for abuse and, if the preparation or mixture contains a narcotic controlled substance, is formulated in such a manner that it incorporates methods of denaturing or other means so that the preparation or 
                    ( print page 3336)
                    mixture is not liable to be abused or have ill effects, if abused, and so that the narcotic substance cannot in practice be removed. Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23, and 21 CFR 1308.24, the Assistant Administrator has determined that each of the chemical preparations or mixtures generally described in Chart I below and specifically described in the application materials received by DEA is exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822-823, 825-829, and 952-954) of the CSA, and 21 CFR 1301.74, as of the date that was provided in the approval letters to the individual requesters. Scope of Approval The exemptions are applicable only to the precise preparation or mixture described in the application submitted to DEA in the form(s) listed in this order and only for those above mentioned sections of the CSA and the CFR. In accordance with 21 CFR 1308.24(h), any change in the quantitative or qualitative composition of the preparation or mixture, or change in the trade name or other designation of the preparation or mixture after the date of application requires a new application. The requirements set forth in 21 CFR 1308.24(b)-(e) apply to the exempted materials. In accordance with 21 CFR 1308.24(g), DEA may prescribe requirements other than those set forth in 21 CFR 1308.24(b)-(e) on a case-by-case basis for materials exempted in bulk quantities. Accordingly, in order to limit opportunity for diversion from the larger bulk quantities, DEA has determined that each of the exempted bulk products listed in this order may only be used in-house by the manufacturer, and may not be distributed for any purpose, or transported to other facilities. Additional exempt chemical preparation requests received between April 1, 2021, and June 30, 2021, and not otherwise referenced in this order, may remain under consideration until DEA receives additional information required, pursuant to 21 CFR 1308.23(d), as detailed in separate correspondence to individual requesters. DEA's order on such requests will be communicated to the public in a future 
                    **Federal Register**
                     publication. DEA also notes that these exemptions are limited to exemption from only those sections of the CSA and the CFR that are specifically identified in 21 CFR 1308.24(a). All other requirements of the CSA and the CFR apply, including registration as an importer as required by 21 U.S.C. 957. Chart I
Supplier
Product name
Form
Application
                             dateAalto Scientific, Ltd
Immunoassay Base (Level A-E)
Glass or plastic bottle or flask: 500 mL-1 L
4/13/2021Aalto Scientific, Ltd
Immunoassay Base (Level A-E)
Glass or plastic bottle or flask: 100 mL-500 mL
4/13/2021Aalto Scientific, Ltd
Immunoassay Base (Level A-E)
Glass or plastic bottle or flask: 1 mL-100 mL
4/13/2021Aalto Scientific, Ltd
Immunoassy Base (Level A-E)
Glass vial, bottle, or flask: 1 mL
4/1/2021Aalto Scientific, Ltd
TDM Base (Level A-E)
Glass vial, bottle, or flask: 500 mL-1L
4/1/2021Aalto Scientific, Ltd
TDM Base (Level A-E)
Glass vial, bottle, or flask: 100mL-500 mL
4/1/2021Aalto Scientific, Ltd
TDM Base (Level A-E)
Glass vial, bottle, or flask: 1 mL-100 mL
4/1/2021Aalto Scientific, Ltd
TDM Beckman AU Base (Level A-E)
Glass vial, bottle, or flask: 500 mL-1L
4/1/2021Aalto Scientific, Ltd
TDM Beckman AU Base (Level A-E)
Glass vial, bottle, or flask: 100mL-500 mL
4/1/2021Aalto Scientific, Ltd
TDM Beckman AU Base (Level A-E)
Glass vial, bottle, or flask: 1 mL-100 mL
4/1/2021ARK Diagnostics, Inc
DRI Fentanyl II Control
Kit: 4 Dropper vials, 10 mL each
4/15/2021ARK Diagnostics, Inc
DRI Fentanyl II Cutoff Calibrator
Kit: 2 Dropper vials, 10 mL each
4/15/2021Audit MicroControls
Linearity FD Fertility Siemens Atellica/Centaur
Kit: 5 vials; 3 mL each
4/29/2021Audit MicroControls
Linearity FD Fertility Siemens Atellica/Centaur, Set 2 Level A
Glass vial: 3 mL
4/29/2021Audit MicroControls
Linearity FD Fertility Siemens Atellica/Centaur, Set 2 Level B
Glass vial: 3 mL
4/29/2021Audit MicroControls
Linearity FD Fertility Siemens Atellica/Centaur, Set 2 Level C
Glass vial: 3 mL
4/29/2021Audit MicroControls
Linearity FD Fertility Siemens Atellica/Centaur, Set 2 Level D
Glass vial: 3 mL
4/29/2021Audit MicroControls
Linearity FD Fertility Siemens Atellica/Centaur, Set 2 Level E
Glass vial: 3 mL
4/29/2021Audit MicroControls
Linearity FD TDM Siemens Atellica/Centaur
Kit: 5 vials; 5 mL each
4/27/2021Cayman Chemical Company
(S)-5-fluoro ADB (CRM); 100 μg/mL in Acetonitrile
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
2′-fluoro ortho-Fluorofentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4-ANPP (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4-ANPP (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4-ANPP-13C6 (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4-ANPP-d5 (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4-ANPP-d5 (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4′-chloro-α-Pyrrolidinovalerophenone (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4-cyano CUMYL-BUTINACA (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4′-methyl Acetyl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4′-methyl Acetyl fentanyl-d5 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4-methyl-α-Ethylaminopentiophenone (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
4′-methyl-α-Pyrrolidinohexanophenone (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
5-fluoro CUMYL-PINACA; 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Acrylfentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Acrylfentanyl-d5 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Butyryl fentanyl-d5 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021( print page 3337)Cayman Chemical Company
Cocaethylene (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Cyclohexyl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Cyclohexyl fentanyl-d5 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Cyclopentyl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Cyclopropyl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Cyclopropyl fentanyl-13C6 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
D8-THCA-A (CRM) 1 mg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D8-THCA-A (CRM) 100 μg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D8-THCH (CRM) 1 mg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D8-THCH (CRM) 1 mg/ml, 1 mL in methanol
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D8-THCH (CRM) 100 μg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D8-THCH (CRM) 100 μg/ml, 1 mL in methanol
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCB (CRM) 100 μg/mL, 1 mL acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCB (CRM) 1 mg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCB (CRM) 1 mg/ml, 1 mL methanol
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCB (CRM) 100 μg/mL, 1 mL methanol
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCBA-A (CRM) 1 mg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCBA-A (CRM) 100 μg/mL, 1 mL acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCH (CRM) 1 mg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCH (CRM) 1 mg/ml, 1 mL in methanol
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCH (CRM) 100 μg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCH (CRM) 100 μg/ml, 1 mL in methanol
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCHA-A (CRM) 1 mg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCHA-A (CRM) 100 μg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCP (CRM) 1 mg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCP (CRM) 1 mg/ml, 1 mL methanol
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCP (CRM) 100 μg/mL, 1 mL acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCP (CRM) 100 μg/mL, 1 mL methanol
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCPA-A (CRM) 1 mg/ml, 1 mL in acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
D9-THCPA-A (CRM) 100 μg/mL, 1 mL acetonitrile
Glass ampule: 1 mL
6/8/2021Cayman Chemical Company
FIBF (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
FIBF-d7 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Furanyl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Furanyl fentanyl-13C6 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Furanyl fentanyl-d5 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Isobutyryl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Isobutyryl fentanyl-d5 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Lorcaserin (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
meta-Fluorobutyryl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
meta-Fluoroisobutyryl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Methoxyacetyl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
MMB-FUBINACA (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
MT-45-d11 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
N-ethyl Pentylone (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Ocfentanil (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Ocfentanil-d5 (hydrochloride); 100 μg/mL in Methanol (CRM)
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
ortho-Fluorobutyryl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
ortho-Fluoroisobutyryl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
para-Chloroisobutyryl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
para-Fluorobutyryl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
para-Fluorobutyryl fentanyl-13C6 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
para-Fluorobutyryl fentanyl-d7 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
para-Fluorofentanyl-d5 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
para-methoxy-Butyryl fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
para-methoxy-Butyryl fentanyl-d7 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
PV8 (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Tetrahydrofuran fentanyl (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Valeryl fentanyl (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Valeryl fentanyl-13C6 (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
Valeryl fentanyl-d5 (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
α-Ethylaminohexanophenone (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cayman Chemical Company
α-Pyrrolidinohexanophenone (hydrochloride) (CRM); 100 μg/mL in Methanol
Glass ampule: 1.0 mL
4/14/2021Cerilliant Corporation
6-Acetylcodeine-D3
Glass ampule: 1.0 mL
4/15/2021Cerilliant Corporation
Normorphine-D3
Glass ampule: 1.0 mL
4/15/2021Cliniqa Corporation
TDM + MTX Control Level 1, Part: 43746
Bottle: 500 ml
4/27/2021Cliniqa Corporation
TDM + MTX Control Level 1, Part: 83737
Vial: 5 ml
4/27/2021Cliniqa Corporation
TDM + MTX Control Level 2, Part: 43747
Bottle: 500 ml
4/27/2021( print page 3338)Cliniqa Corporation
TDM + MTX Control Level 2, Part: 83738
Vial: 5 ml
4/27/2021Cliniqa Corporation
TDM + MTX Control Level 3, Part: 43747
Bottle: 500 ml
4/27/2021Cliniqa Corporation
TDM + MTX Control Level 3, Part: 83739
Vial: 5 ml
4/27/2021College of American Pathologists
2022 DMPM-01
HDPE bottle: 40 mL
4/19/2021College of American Pathologists
2022 DMPM-02
HDPE bottle: 40 mL
4/19/2021College of American Pathologists
2022 DMPM-03
HDPE bottle: 40 mL
4/19/2021College of American Pathologists
2022 DMPM-05
HDPE bottle: 40 mL
4/19/2021College of American Pathologists
2022 DMPM-06
HDPE bottle: 40 mL
4/19/2021College of American Pathologists
2022 DMPM-07
HDPE bottle: 40 mL
4/19/2021College of American Pathologists
2022 FTC-02
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 FTC-03
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 FTC-04
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 FTC-05
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 FTC-07
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 FTC-08
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 FTC-10
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 FTC-12
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 FTC-13
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 FTC-14
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 OFD-01
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-02
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-03
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-04
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-05
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-06
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-07
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-08
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-10
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-11
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-12
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-13
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-14
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-15
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-16
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-17
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-18
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-19
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 OFD-20
HDPE vial: 2 mL
4/19/2021College of American Pathologists
2022 T-03
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 T-04
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 T-05
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 T-07
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 T-08
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 T-09
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 T-12
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 T-13
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022 THCB-01
Glass vial: 10 mL
4/19/2021College of American Pathologists
2022 THCB-02
Glass vial: 10 mL
4/19/2021College of American Pathologists
2022 THCB-03
Glass vial: 10 mL
4/19/2021College of American Pathologists
2022 THCB-04
Glass vial: 10 mL
4/19/2021College of American Pathologists
2022 THCB-05
Glass vial: 10 mL
4/19/2021College of American Pathologists
2022 THCB-06
Glass vial: 10 mL
4/19/2021College of American Pathologists
2022 UDS-01
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-02
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-03
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-04
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-05
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-06
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-07
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-08
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-09
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-10
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-11
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-12
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-13
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-14
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UDS-15
HDPE bottle: 10 mL
4/19/2021College of American Pathologists
2022 UT-01
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-02
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-03
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-04
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-05
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-06
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-07
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-08
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-09
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-10
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-11
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-12
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-13
HDPE bottle: 50 mL
4/19/2021( print page 3339)College of American Pathologists
2022 UT-14
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UT-15
HDPE bottle: 50 mL
4/19/2021College of American Pathologists
2022 UTCO-01
HDPE bottle: 40 mL
4/19/2021College of American Pathologists
2022 ZE-01
Glass vial: 5 mL
4/19/2021College of American Pathologists
2022 ZE-02
Glass vial: 5 mL
4/19/2021College of American Pathologists
2022 ZE-03
Glass vial: 5 mL
4/19/2021College of American Pathologists
2022 ZE-04
Glass vial: 5 mL
4/19/2021College of American Pathologists
2022 ZE-05
Glass vial: 5 mL
4/19/2021College of American Pathologists
2022 ZE-06
Glass vial: 5 mL
4/19/2021College of American Pathologists
2022FTC-01
HDPE bottle: 20 mL
4/19/2021College of American Pathologists
2022-OFD-09
HDPE vial: 2 mL
4/19/2021CPI International
(-)-delta9-tetrahydrocannabinol (d9-THC) 1000 mg/L, 1 mL
Amber ampule: 1 mL
4/7/2021LGC—Dr. Ehrenstorfer
Custom (-)-delta9-tetrahydrocannabinol (d9-HC) 1000 μg/mL in acetonitrile
Amber ampule: 1 mL
4/12/2021LGC—Dr. Ehrenstorfer
Custom Pharmaceutical Mix 6509 100-10000 μg/mL in methanol
Amber ampule: 1 mL
6/8/2021LGC—Dr. Ehrenstorfer
Custom Pharmaceutical Mix 6509 100-10000 μg/mL in methanol
1 kit: 5 ampules × 1 mL each
4/12/2021LGC—Dr. Ehrenstorfer
Δ11-Tetrahydrocannabinol (Δ11-THC) 100 μg/mL in Methanol
Amber ampule: 1 mL
6/14/2021LGC—Dr. Ehrenstorfer
Δ11-Tetrahydrocannabinol (Δ11-THC) 100 μg/mL in Methanol
Amber ampule: 1 mL
4/20/2021LGC—Dr. Ehrenstorfer
Δ11-Tetrahydrocannabinol (Δ11-THC) 1000 μg/mL in Methanol
Amber ampule: 1 mL
6/14/2021LGC—Dr. Ehrenstorfer
Δ11-Tetrahydrocannabinol (Δ11-THC) 1000 μg/mL in Methanol
Amber ampule: 1 mL
4/20/2021LGC—Dr. Ehrenstorfer
Δ9-Tetrahydrocannabivarinic acid (THCVA) 100 μg/mL in Methanol
Amber ampule: 1 mL
6/8/2021LGC—Dr. Ehrenstorfer
Δ9-Tetrahydrocannabivarinic acid (THCVA) 1000 μg/mL in Methanol
Amber ampule: 1 mL
6/8/2021LGC—Dr. Ehrenstorfer
Boldenone cypionate 100 μg/mL in Acetonitrile
Amber ampule: 1 mL
5/4/2021Lin-Zhi International
LZI Norfentanyl (Q) Qualitative Calibrator (5 ng/mL), Ref# C68815
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
LZI Norfentanyl Level 1 Control (3.75 ng/mL), Ref# C68821
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
LZI Norfentanyl Level 2 Control (6.25 ng/mL), Ref# C68822
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
LZI Norfentanyl Qualitative Calibrator (5 ng/mL), Ref# C68810
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
LZI Norfentanyl Semi-Quantitative Calibrator Set, Ref# C68811
Kit: 4 dropper bottles; 15 mL each
6/9/2021Lin-Zhi International
Norbuprenorphine DAU Calibrator, Norbuprcnorphinc, Intermediate Calibrator #2 (40 ng/mL), Ref# A68829
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
Norbuprenorphine DAU Calibrator, Norbuprenorphine Level 2 Control (13 ng/mL), Ref# A68825
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
Norbuprenorphine DAU Calibrator, Norbuprenorphine Low Calibrator (5 ng/mL), Ref# A68826
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
Norbuprenorphine DAU Calibrator, Norbuprenorphine, Cutoff Calibrator (10 ng/mL), Ref# A68827
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
Norbuprenorphine DAU Calibrator, Norbuprenorphine, High Calibrator (100 ng/mL), Ref# A68830
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
Norbuprenorphine DAU Calibrator, Norbuprenorphine, Intermediate Calibrator #1 (20 ng/mL), Ref# A68828
Dropper bottle: 5 mL
6/9/2021Lin-Zhi International
Norbuprenorphine DAU Calibrator, Norbuprenorphine, Level 1 Control (7 ng/mL), Ref# A68824
Dropper bottle: 5 mL
6/9/2021Microgenics Corporation
Alinity c Benzodiazepines Qual Calibrator Kit, Catalog Number: 10027281/09P5201
Kit: 1 vial, 2.9 mL
4/2/2021Microgenics Corporation
Alinity c Cannabinoids Control 1 Kit, Catalog Number: 10024827/09P5410
Kit: 2 LDPE, 5 mL each
4/2/2021Microgenics Corporation
Alinity c Cannabinoids Control 2 Kit, Catalog Number: 10027212/09P5411
Kit: 1 LDPE, 5 mL
4/2/2021Microgenics Corporation
Alinity c Cannabinoids Qual Calibrator, Catalog Number: 10024821/09P5401
Kit: 1 vial, 3.0 mL
4/2/2021Microgenics Corporation
Alinity c Cannabinoids SemiQuant 100 Calibrator Kit, Catalog Number: 10026530/09P5402
Kit: 3 vials, 3 mL each
4/2/2021Microgenics Corporation
Alinity c Cannabinoids SemiQuant 200 Calibrator Kit, Catalog Number: 10026531/09P5403
Kit: 3 vials, 3 mL each
4/2/2021Microgenics Corporation
Alinity c Ecstasy Qual Calibrator Kit, Catalog Number: 10024822/09P5801
Kit: 1 vial, 3.0 mL
4/2/2021Microgenics Corporation
Alinity c Ecstasy Semiquant Calibrator Kit, Catalog Number: 10026532/09P5802
Kit: 4 vials, 3.0 mL each
4/2/2021Microgenics Corporation
Alinity c Opiates Qual Calibrator Kit, Catalog Number: 10024823/09P6501
Kit: 1 vial, 3.0 mL
4/2/2021Microgenics Corporation
Alinity c Opiates Semiquant Calibrator Kit, Catalog Number: 10026534/09P6502
Kit: 4 vials, 3 mL each
4/2/2021o2si Smart Solutions
Codeine monohydrate as codeine Solution, 2,000 mg/L—Parent Stock Solution—Not For Sale
Glass cryule: 2 mL
5/28/2021o2si Smart Solutions
Heroin Solution, 2,000 mg/L—Parent Stock Solution—Not For Sale
Glass cryule: 2 mL
5/28/2021o2si Smart Solutions
Hydrocodone (+)-bitartrate salt as hydrocodone Solution, 2,000 mg/L—Parent Stock Solution—Not For Sale
Glass cryule: 2 mL
5/28/2021o2si smart solutions
ISO 17034—Custom Toxin/Poison Standard Kit, 45-46, 100 mg/L, 1 × 1 ml of Each Level (G34-140319-01, G34-140339-01, G34-140340-01)
Kit: 2 amber ampules, 1 mL each
5/28/2021o2si smart solutions
ISO 17034 Custom Toxin/Poison Stock Standard Mix, 10-318, 100 mg/L, 1 mL
Amber ampule: 1 mL
5/28/2021o2si smart solutions
ISO 17034 Custom Toxin/Poison Stock Standard Mix, 10-319, 100 mg/L, 1 mL
Amber ampule: 1 mL
5/28/2021o2si smart solutions
ISO 17034 Custom Toxin/Poison Stock Standard Mix, 34-318, 100 mg/L, 1 mL
Amber ampule: 1 mL
5/27/2021o2si Smart Solutions
ISO 17034 Custom Toxin/Poison Stock Standard Mix, 34-318, 100 mg/L, 1 mL
Amber ampule: 1 mL
4/26/2021o2si smart solutions
Levorphanol (+)-tartrate salt dehydrate as levorphanol Solution, 2,000 mg/L—Parent Stock Solution—Not For Sale
Glass cryule: 2 mL
5/28/2021( print page 3340)o2si Smart Solutions
Oxycodone Solution, 2,000 mg/L—Parent Stock Solution—Not For Sale
Glass cryule: 2 mL
5/28/2021o2si Smart Solutions
Pentazocine Solution, 2,000 mg/L—Parent Stock Solution
Glass cryule: 2 mL
5/28/2021Restek Corporation
Custom D-Methamphetamine Standard
Glass Ampule: 1.3 mL
4/15/2021UTAK Laboratories, Inc
DAU High Cutoff 1 Urine Control
Kit: 4 bottles, 10 mL each
4/16/2021UTAK Laboratories, Inc
DAU High Cutoff 2 Urine Control
Kit: 4 bottles, 10 mL each
4/16/2021UTAK Laboratories, Inc
DAU Low Cutoff 1 Urine Control
Kit: 4 bottles, 10 mL each
4/16/2021UTAK Laboratories, Inc
DAU Low Cutoff 2 Urine Control
Kit: 4 bottles, 10 mL each
4/16/2021UTAK Laboratories, Inc
Drugs of Abuse Level 1 Whole Blood Control
Kit: 5 bottles, 5 mL each
4/16/2021UTAK Laboratories, Inc
Fentanyl Analogues 2 NG/ML Whole Blood Control
Kit: 5 bottles, 3 mL each
4/16/2021UTAK Laboratories, Inc
Fentanyl Analogues 5 NG/ML Urine Control
Kit: 5 bottles, 3 mL each
4/16/2021UTAK Laboratories, Inc
PM 100 Urine Control
Kit: 5 bottles, 5 mL each
4/16/2021UTAK Laboratories, Inc
PM 100 Whole Blood Control
Kit: 5 bottles, 5 mL each
4/16/2021UTAK Laboratories, Inc
PM Plus High Urine Control
Kit: 5 bottles, 5 mL each
4/16/2021UTAK Laboratories, Inc
PM Plus Low Urine Control
Kit: 5 bottles, 5 mL each
4/16/2021UTAK Laboratories, Inc
SAMHSA Confirm Level 1 SMX Oral Fluid Control
Kit: 5 bottles, 3 mL each
4/16/2021UTAK Laboratories, Inc
SAMHSA Confirm Level 2 SMX Oral Fluid Control
Kit: 5 bottles, 3 mL each
4/16/2021
 The Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart II below is not consistent with the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23. Accordingly, the Assistant Administrator has determined that the chemical preparations or mixtures generally described in Chart II below and specifically described in the application materials received by DEA, are not exempt from application of any part of the CSA or from application of any part of the CFR, with regard to the requested exemption pursuant to 21 CFR 1308.23, as of the date that was provided in the determination letters to the individual requesters. Chart II
Supplier
Product name
Form
Application
                             dateAalto Scientific, Ltd
Immunoassy Base (Level A-E)
Glass vial, bottle, or flask: 500 mL-1L
4/1/2021Aalto Scientific, Ltd
Immunoassy Base (Level A-E)
Glass vial, bottle, or flask: 100mL-500 mL
4/1/2021Aalto Scientific, Ltd
Immunoassy Base (Level A-E)
Glass vial, bottle, or flask: 100 mL
4/1/2021
 Opportunity for Comment Pursuant to 21 CFR 1308.23(e), any interested person may submit written comments on or objections to any chemical preparation in this order that has been approved or denied as exempt. If any comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which this order is based, the Assistant Administrator will immediately suspend the effectiveness of any applicable part of this order until he may reconsider the application in light of the comments and objections filed. Thereafter, the Assistant Administrator shall reinstate, revoke, or amend his original order as he determines appropriate. Approved Exempt Chemical Preparations Are Posted on the DEA's Website A list of all current exemptions, including those listed in this order, is available on the DEA's website at 
                    *http://www.DEAdiversion.usdoj.gov/​schedules/​exempt/​exempt_​chemlist.pdf.*
                     The dates of applications of all current exemptions are posted for easy reference. 
 Brian S. Besser, Acting Assistant Administrator.


# Footnotes

1.
    
                         This authority has been delegated from the Attorney General to the DEA Administrator by 28 CFR 0.100, and subsequently redelegated to the Deputy Assistant Administrator pursuant to 28 CFR 0.104 and Section 7 of the appendix to subpart R of part 0. Back to Citation


[FR Doc. 2022-01125 Filed 1-20-22; 8:45 am] BILLING CODE 4410-09-P